drugset / Trial / NCT02847702

A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee

NCT02847702

Phase 2 Terminated 75 enrolled Purdue Pharma LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of VM902A twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.

Timeline

Start
2016-08
Primary completion
2016-11-22
Completion
2016-11-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg Oral
Subject VM902A Unknown 200 mg Oral
Subject VM902A Unknown 400 mg Oral

Indications